XTL Biopharmaceuticals Ltd. (XTLB)
USD 1.4
(13.82%)
USD 1.4
(13.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.42 Million USD | -42.04% |
| 2022 | 4.18 Million USD | -36.75% |
| 2021 | 6.61 Million USD | 1.77% |
| 2020 | 6.5 Million USD | -9.83% |
| 2019 | 7.21 Million USD | -15.9% |
| 2018 | 8.57 Million USD | 30.2% |
| 2017 | 6.58 Million USD | 118.3% |
| 2016 | 3.01 Million USD | -43.32% |
| 2015 | 5.32 Million USD | -5.69% |
| 2014 | 5.64 Million USD | -29.58% |
| 2013 | 8.01 Million USD | -27.7% |
| 2012 | 11.08 Million USD | 166.55% |
| 2011 | 4.15 Million USD | 9.53% |
| 2010 | 3.79 Million USD | 431.05% |
| 2009 | 715 Thousand USD | -79.15% |
| 2008 | 3.43 Million USD | -75.72% |
| 2007 | 14.12 Million USD | -47.48% |
| 2006 | 26.9 Million USD | 77.55% |
| 2005 | 15.15 Million USD | -40.87% |
| 2004 | 25.62 Million USD | 3.1% |
| 2003 | 24.85 Million USD | -35.32% |
| 2002 | 38.42 Million USD | -30.27% |
| 2001 | 55.1 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.92 Million USD | 20.69% |
| 2023 Q1 | 3.32 Million USD | -20.64% |
| 2023 Q2 | 2.88 Million USD | -13.28% |
| 2023 Q3 | 2.66 Million USD | -7.57% |
| 2023 FY | 2.42 Million USD | -42.04% |
| 2023 Q4 | 2.42 Million USD | -8.9% |
| 2022 FY | 4.18 Million USD | -36.75% |
| 2022 Q1 | 6.62 Million USD | 0.05% |
| 2022 Q3 | 4.89 Million USD | -14.94% |
| 2022 Q4 | 4.18 Million USD | -14.52% |
| 2022 Q2 | 5.75 Million USD | -13.05% |
| 2021 FY | 6.61 Million USD | 1.77% |
| 2021 Q3 | 6.85 Million USD | -1.41% |
| 2021 Q1 | 7.31 Million USD | 12.43% |
| 2021 Q4 | 6.61 Million USD | -3.46% |
| 2021 Q2 | 6.95 Million USD | -4.9% |
| 2020 Q4 | 6.5 Million USD | 4.72% |
| 2020 FY | 6.5 Million USD | -9.83% |
| 2020 Q3 | 6.21 Million USD | -8.53% |
| 2020 Q1 | 7.26 Million USD | 0.79% |
| 2020 Q2 | 6.78 Million USD | -6.6% |
| 2019 Q4 | 7.21 Million USD | -12.99% |
| 2019 FY | 7.21 Million USD | -15.9% |
| 2019 Q3 | 8.28 Million USD | -13.19% |
| 2019 Q2 | 9.54 Million USD | -23.21% |
| 2019 Q1 | 12.43 Million USD | 45.0% |
| 2018 Q3 | 7.46 Million USD | 16.05% |
| 2018 Q4 | 8.57 Million USD | 14.81% |
| 2018 FY | 8.57 Million USD | 30.2% |
| 2018 Q1 | 6.42 Million USD | -2.38% |
| 2018 Q2 | 6.43 Million USD | 0.11% |
| 2017 Q2 | 7.17 Million USD | -8.0% |
| 2017 Q1 | 7.79 Million USD | 158.4% |
| 2017 Q4 | 6.58 Million USD | -3.5% |
| 2017 Q3 | 6.82 Million USD | -4.84% |
| 2017 FY | 6.58 Million USD | 118.3% |
| 2016 Q1 | 4.75 Million USD | -10.61% |
| 2016 FY | 3.01 Million USD | -43.32% |
| 2016 Q4 | 3.01 Million USD | -25.62% |
| 2016 Q3 | 4.05 Million USD | -6.48% |
| 2016 Q2 | 4.33 Million USD | -8.85% |
| 2015 Q2 | 7.86 Million USD | 56.81% |
| 2015 Q3 | 7.48 Million USD | -4.78% |
| 2015 Q4 | 5.32 Million USD | -28.88% |
| 2015 Q1 | 5.01 Million USD | -11.18% |
| 2015 FY | 5.32 Million USD | -5.69% |
| 2014 Q1 | 7.74 Million USD | -3.39% |
| 2014 FY | 5.64 Million USD | -29.58% |
| 2014 Q4 | 5.64 Million USD | -15.61% |
| 2014 Q2 | 7.22 Million USD | -6.7% |
| 2014 Q3 | 6.68 Million USD | -7.42% |
| 2013 FY | 8.01 Million USD | -27.7% |
| 2013 Q3 | 10.28 Million USD | 9.62% |
| 2013 Q4 | 8.01 Million USD | -22.05% |
| 2013 Q2 | 9.38 Million USD | -9.99% |
| 2013 Q1 | 10.42 Million USD | -49.19% |
| 2012 Q1 | 7.86 Million USD | 93.05% |
| 2012 FY | 11.08 Million USD | 166.55% |
| 2012 Q2 | 7.33 Million USD | -6.68% |
| 2012 Q4 | 20.51 Million USD | 161.04% |
| 2012 Q3 | 7.85 Million USD | 7.07% |
| 2011 Q4 | 4.07 Million USD | -6.67% |
| 2011 Q1 | 5.12 Million USD | 34.92% |
| 2011 FY | 4.15 Million USD | 9.53% |
| 2011 Q2 | 4.73 Million USD | -7.55% |
| 2011 Q3 | 4.36 Million USD | -7.85% |
| 2010 Q2 | 392 Thousand USD | -23.29% |
| 2010 Q4 | 3.79 Million USD | -4.96% |
| 2010 FY | 3.79 Million USD | 431.05% |
| 2010 Q3 | 3.99 Million USD | 919.13% |
| 2010 Q1 | 511 Thousand USD | -28.53% |
| 2009 Q4 | 715 Thousand USD | -18.1% |
| 2009 Q3 | 873 Thousand USD | 0.0% |
| 2009 FY | 715 Thousand USD | -79.15% |
| 2008 Q2 | 9.38 Million USD | 0.0% |
| 2008 FY | 3.43 Million USD | -75.72% |
| 2008 Q4 | 3.43 Million USD | 0.0% |
| 2007 FY | 14.12 Million USD | -47.48% |
| 2007 Q4 | 14.12 Million USD | 0.0% |
| 2007 Q2 | 13.56 Million USD | 0.0% |
| 2006 FY | 26.9 Million USD | 77.55% |
| 2006 Q2 | 33.8 Million USD | 0.0% |
| 2006 Q4 | 26.9 Million USD | 0.0% |
| 2005 Q4 | 15.15 Million USD | 0.0% |
| 2005 FY | 15.15 Million USD | -40.87% |
| 2005 Q2 | 19.97 Million USD | 0.0% |
| 2004 FY | 25.62 Million USD | 3.1% |
| 2004 Q4 | 25.62 Million USD | 0.0% |
| 2004 Q2 | 16.28 Million USD | 0.0% |
| 2003 FY | 24.85 Million USD | -35.32% |
| 2002 FY | 38.42 Million USD | -30.27% |
| 2001 FY | 55.1 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 99.837% |
| Alkermes plc | 2.13 Billion USD | 99.886% |
| Agenus Inc. | 313.91 Million USD | 99.227% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.937% |
| Aptorum Group Limited | 20.64 Million USD | 88.246% |
| Ardelyx, Inc. | 297.57 Million USD | 99.185% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 99.683% |
| Bicycle Therapeutics plc | 595.34 Million USD | 99.593% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 96.708% |
| ChromaDex Corporation | 54.96 Million USD | 95.586% |
| Chimerix, Inc. | 212.77 Million USD | 98.86% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 91.419% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 99.45% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 99.891% |
| Precision BioSciences, Inc. | 159.78 Million USD | 98.482% |
| Dyadic International, Inc. | 8.21 Million USD | 70.484% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 92.357% |
| Fortress Biotech, Inc. | 167.52 Million USD | 98.552% |
| Lantern Pharma Inc. | 43.64 Million USD | 94.442% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 98.496% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | 83.277% |
| Incyte Corporation | 6.78 Billion USD | 99.964% |
| IO Biotech, Inc. | 150.71 Million USD | 98.39% |
| Jaguar Health, Inc. | 50.76 Million USD | 95.221% |
| Novavax, Inc. | 1.85 Billion USD | 99.869% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 99.362% |
| Opthea Limited | 188.79 Million USD | 98.715% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 99.709% |
| ContextLogic Inc. | 423 Million USD | 99.426% |
| MiMedx Group, Inc. | 239.04 Million USD | 98.985% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 98.604% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | 53.073% |
| NextCure, Inc. | 129.41 Million USD | 98.125% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 95.503% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 93.395% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 92.489% |
| Vaxcyte, Inc. | 1.4 Billion USD | 99.828% |
| PDS Biotechnology Corporation | 59.39 Million USD | 95.915% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 99.621% |
| Pharming Group N.V. | 462.85 Million USD | 99.476% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 93.728% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 99.614% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 87.18% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 87.18% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 98.533% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 94.643% |
| Acelyrin, Inc. | 742.69 Million USD | 99.673% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | 63.167% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | 62.112% |
| Summit Therapeutics Inc. | 202.94 Million USD | 98.805% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 96.738% |
| Senti Biosciences, Inc. | 119.48 Million USD | 97.97% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 98.938% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 98.557% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | 70.64% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | 49.181% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 99.483% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 98.038% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 99.118% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.487% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 75.992% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 98.869% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -114.281% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 99.414% |
| Immix Biopharma, Inc. | 19.92 Million USD | 87.824% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 99.344% |
| MEI Pharma, Inc. | 41.37 Million USD | 94.137% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 92.514% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 99.288% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 97.93% |
| Fortress Biotech, Inc. | 167.52 Million USD | 98.552% |
| Precigen, Inc. | 151.04 Million USD | 98.394% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 92.868% |
| AlloVir, Inc. | 190.79 Million USD | 98.728% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 99.356% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 99.521% |
| ImmuCell Corporation | 43.8 Million USD | 94.462% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 99.626% |
| Onconetix, Inc. | 88.82 Million USD | 97.269% |
| PureTech Health plc | 693.97 Million USD | 99.65% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 97.517% |
| Elevation Oncology, Inc. | 89.09 Million USD | 97.277% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | 60.884% |
| Seer, Inc. | 436.26 Million USD | 99.444% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 97.027% |
| Innoviva, Inc. | 1.24 Billion USD | 99.805% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 98.168% |
| ESSA Pharma Inc. | 149.12 Million USD | 98.373% |
| GlycoMimetics, Inc. | 45.31 Million USD | 94.647% |
| GT Biopharma, Inc. | 14.1 Million USD | 82.805% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 99.212% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 98.996% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 99.486% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 95.215% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 97.452% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -284.111% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 99.572% |
| Aptose Biosciences Inc. | 12.92 Million USD | 81.227% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | 89.03% |
| Soligenix, Inc. | 9.79 Million USD | 75.238% |
| Century Therapeutics, Inc. | 360.69 Million USD | 99.327% |
| Kura Oncology, Inc. | 448.93 Million USD | 99.46% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 99.109% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | 85.973% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 97.813% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 98.817% |
| Autolus Therapeutics plc | 375.38 Million USD | 99.354% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 99.036% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 99.317% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 95.062% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 99.633% |
| GRI Bio, Inc. | 2.95 Million USD | 17.93% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | 77.124% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 98.577% |
| IGM Biosciences, Inc. | 423.41 Million USD | 99.427% |
| INmune Bio, Inc. | 57 Million USD | 95.744% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 98.91% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 97.11% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 90.711% |
| Entero Therapeutics, Inc. | 6.88 Million USD | 64.755% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 96.775% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 98.353% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 98.534% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 99.615% |
| Verastem, Inc. | 149.71 Million USD | 98.38% |
| Abeona Therapeutics Inc. | 64 Million USD | 96.209% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 99.526% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 98.429% |
| Histogen Inc. | 19.07 Million USD | 87.28% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | 89.289% |
| Surrozen, Inc. | 46.08 Million USD | 94.735% |
| Organovo Holdings, Inc. | 6.34 Million USD | 61.789% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 43.694% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 98.316% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 79.444% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 96.777% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | 71.523% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 99.332% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | 86.593% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 99.435% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | 80.764% |
| Apollomics, Inc. | 55.38 Million USD | 95.62% |
| Amarin Corporation plc | 831.68 Million USD | 99.708% |
| Mesoblast Limited | 669.15 Million USD | 99.637% |
| Turnstone Biologics Corp. | 112.81 Million USD | 97.85% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 99.579% |
| Synaptogenix, Inc. | 31.11 Million USD | 92.203% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | 80.089% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 99.557% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 58.687% |
| Monopar Therapeutics Inc. | 7.34 Million USD | 66.971% |
| Exelixis, Inc. | 2.94 Billion USD | 99.918% |
| Better Therapeutics, Inc. | 22.94 Million USD | 89.426% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 99.335% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 99.692% |
| NLS Pharmaceutics AG | 1.84 Million USD | -31.374% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | 69.594% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 83.491% |
| Gritstone bio, Inc. | 177.76 Million USD | 98.635% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 97.456% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | 86.418% |
| Avid Bioservices, Inc. | 336.55 Million USD | 99.279% |
| Insmed Incorporated | 1.32 Billion USD | 99.818% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | 74.804% |
| MediWound Ltd. | 66.45 Million USD | 96.35% |
| OmniAb, Inc. | 401.98 Million USD | 99.396% |
| Alector, Inc. | 621.82 Million USD | 99.61% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 99.323% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | 54.89% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 95.721% |
| Zai Lab Limited | 1.03 Billion USD | 99.766% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 99.493% |
| Aura Biosciences, Inc. | 255.07 Million USD | 99.049% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 99.677% |
| Immunic, Inc. | 54.29 Million USD | 95.532% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 99.089% |
| Veracyte, Inc. | 1.13 Billion USD | 99.787% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | 79.48% |
| FibroGen, Inc. | 423.52 Million USD | 99.427% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | 30.942% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | 48.782% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | 55.318% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.979% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | 72.447% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 99.531% |
| TG Therapeutics, Inc. | 329.58 Million USD | 99.264% |
| Galecto, Inc. | 38.22 Million USD | 93.654% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 91.54% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.944% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 98.969% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | 90.234% |
| XBiotech Inc. | 227.24 Million USD | 98.932% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 97.456% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 98.299% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 99.151% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 98.103% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 99.365% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 99.837% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 99.335% |
| Vaxxinity, Inc. | 44.35 Million USD | 94.53% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 99.531% |
| Gain Therapeutics, Inc. | 18.6 Million USD | 86.964% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 99.205% |
| NexImmune, Inc. | 8.59 Million USD | 71.771% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | 77.359% |
| Marker Therapeutics, Inc. | 17.12 Million USD | 85.836% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.993% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | 89.048% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -518.459% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 98.6% |
| Ainos, Inc. | 31.84 Million USD | 92.381% |
| Pluri Inc. | 39.52 Million USD | 93.862% |
| Prothena Corporation plc | 696.38 Million USD | 99.652% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 99.142% |
| Celularity Inc. | 143.88 Million USD | 98.314% |
| Rallybio Corporation | 115.62 Million USD | 97.902% |
| Cue Biopharma, Inc. | 61.53 Million USD | 96.057% |
| MeiraGTx Holdings plc | 458.16 Million USD | 99.47% |
| Omeros Corporation | 378.26 Million USD | 99.359% |
| Humacyte, Inc. | 128.22 Million USD | 98.108% |
| Immunocore Holdings plc | 597 Million USD | 99.594% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 92.239% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 96.46% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 99.769% |
| CalciMedica, Inc. | 12.18 Million USD | 80.09% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 99.044% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 98.581% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 99.22% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 99.571% |
| Pulmatrix, Inc. | 33.95 Million USD | 92.856% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | 91.063% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 98.278% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 99.814% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 98.137% |
| Cytokinetics, Incorporated | 824.31 Million USD | 99.706% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 88.515% |
| Nutriband Inc. | 7.51 Million USD | 67.727% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 96.927% |
| Vor Biopharma Inc. | 209.82 Million USD | 98.844% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.966% |
| Evogene Ltd. | 51.1 Million USD | 95.253% |
| ProKidney Corp. | 420.55 Million USD | 99.423% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 95.576% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | 74.518% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 99.556% |
| CorMedix Inc. | 82.05 Million USD | 97.044% |
| BioLineRx Ltd. | 63.92 Million USD | 96.205% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 99.397% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 91.397% |
| Atai Life Sciences N.V. | 293.47 Million USD | 99.173% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 98.513% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 98.096% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 99.568% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 97.492% |
| MediciNova, Inc. | 66.26 Million USD | 96.339% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 97.242% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 45.634% |
| GeoVax Labs, Inc. | 9.28 Million USD | 73.867% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 99.588% |
| Biomea Fusion, Inc. | 199.92 Million USD | 98.787% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 99.873% |
| Mereo BioPharma Group plc | 66.49 Million USD | 96.352% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 99.5% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 99.604% |
| Absci Corporation | 234.48 Million USD | 98.965% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 66.835% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 99.286% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 98.53% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 99.539% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 99.126% |
| Allakos Inc. | 243.61 Million USD | 99.004% |
| Imunon, Inc. | 21.91 Million USD | 88.932% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 99.059% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 99.61% |
| BioAtla, Inc. | 119.65 Million USD | 97.973% |
| NLS Pharmaceutics AG | 1.84 Million USD | -31.374% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 24.658% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 99.623% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 97.471% |
| XOMA Corporation | 234.3 Million USD | 98.965% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 98.903% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 98.072% |
| aTyr Pharma, Inc. | 122.06 Million USD | 98.013% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 98.424% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 99.582% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 99.505% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 97.804% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | 83.995% |
| Akari Therapeutics, Plc | 4.35 Million USD | 44.294% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 85.761% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 99.86% |
| Lexaria Bioscience Corp. | 3.08 Million USD | 21.336% |
| UroGen Pharma Ltd. | 178.31 Million USD | 98.639% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 99.485% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -336.555% |
| Orgenesis Inc. | 14.55 Million USD | 83.329% |
| Entera Bio Ltd. | 11.76 Million USD | 79.38% |
| GH Research PLC | 226.3 Million USD | 98.928% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 95.564% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 97.742% |
| Xencor, Inc. | 952.69 Million USD | 99.745% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | 68.833% |
| Replimune Group, Inc. | 487.72 Million USD | 99.503% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | 69.942% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 99.626% |
| Lexaria Bioscience Corp. | 3.08 Million USD | 21.336% |
| Portage Biotech Inc. | 7.77 Million USD | 68.813% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 45.634% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 99.124% |
| OncoCyte Corporation | 74.89 Million USD | 96.761% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -19.316% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | 58.076% |
| Purple Biotech Ltd. | 44.3 Million USD | 94.524% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 92.891% |
| scPharmaceuticals Inc. | 94.47 Million USD | 97.432% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | 86.556% |
| HilleVax, Inc. | 344.43 Million USD | 99.296% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | 23.615% |
| Tharimmune, Inc. | 10.94 Million USD | 77.837% |
| Genprex, Inc. | 10.67 Million USD | 77.265% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 99.511% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 97.48% |
| Virios Therapeutics, Inc. | 4.16 Million USD | 41.759% |
| OKYO Pharma Limited | 1.54 Million USD | -57.403% |
| Savara Inc. | 177.56 Million USD | 98.634% |
| Curis, Inc. | 77.28 Million USD | 96.861% |
| Daré Bioscience, Inc. | 21.28 Million USD | 88.601% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 96.206% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | 69.998% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | 87.476% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.958% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 80.064% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 99.884% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 99.322% |
| Erasca, Inc. | 395.29 Million USD | 99.386% |
| bluebird bio, Inc. | 619.16 Million USD | 99.608% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 43.886% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.965% |
| DBV Technologies S.A. | 182.98 Million USD | 98.674% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 43.886% |
| Moderna, Inc. | 18.42 Billion USD | 99.987% |
| Vincerx Pharma, Inc. | 18.21 Million USD | 86.683% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | 79.061% |
| Molecular Templates, Inc. | 35.38 Million USD | 93.144% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 98.245% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 99.692% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 99.201% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 97.666% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 99.479% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 99.226% |
| MacroGenics, Inc. | 306.82 Million USD | 99.209% |
| RenovoRx, Inc. | 1.46 Million USD | -65.484% |
| Adicet Bio, Inc. | 207.29 Million USD | 98.83% |
| Prime Medicine, Inc. | 193.85 Million USD | 98.749% |
| Aditxt, Inc. | 44.57 Million USD | 94.558% |
| Adagene Inc. | 115.72 Million USD | 97.904% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 45.534% |
| Quantum-Si incorporated | 298.25 Million USD | 99.187% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 99.837% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | 68.531% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 99.309% |
| SciSparc Ltd. | 11.18 Million USD | 78.304% |
| Vericel Corporation | 353.65 Million USD | 99.314% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 80.135% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 95.736% |
| Generation Bio Co. | 374.75 Million USD | 99.353% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 99.047% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 98.47% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 99.289% |
| Invivyd, Inc. | 229.18 Million USD | 98.941% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 99.713% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | 80.065% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 98.67% |
| Artelo Biosciences, Inc. | 20.42 Million USD | 88.122% |
| 2seventy bio, Inc. | 565.42 Million USD | 99.571% |
| ADMA Biologics, Inc. | 329.18 Million USD | 99.263% |
| Clene Inc. | 52.34 Million USD | 95.365% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 95.87% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 98.132% |
| GeoVax Labs, Inc. | 9.28 Million USD | 73.867% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 99.629% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 97.659% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 98.139% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 97.513% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 96.583% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 99.0% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 99.876% |
| Evaxion Biotech A/S | 12.88 Million USD | 81.177% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 99.038% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 99.678% |
| Trevena, Inc. | 40.6 Million USD | 94.025% |
| Surrozen, Inc. | 46.08 Million USD | 94.735% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 98.926% |
| Cingulate Inc. | 3.49 Million USD | 30.516% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | 85.411% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 96.307% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | 79.238% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 99.097% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 99.676% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 98.073% |
| Clearmind Medicine Inc. | 4.32 Million USD | 43.9% |
| Kronos Bio, Inc. | 213.27 Million USD | 98.863% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 98.482% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 71.661% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 99.342% |
| Statera Biopharma, Inc. | 21.16 Million USD | 88.54% |
| ImmunityBio, Inc. | 504.45 Million USD | 99.519% |
| Korro Bio, Inc. | 221.66 Million USD | 98.906% |
| Kineta, Inc. | 10.28 Million USD | 76.403% |
| BioVie Inc. | 25.2 Million USD | 90.376% |
| Codexis, Inc. | 136.56 Million USD | 98.224% |
| Celularity Inc. | 143.88 Million USD | 98.314% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 99.618% |
| Celcuity Inc. | 191.21 Million USD | 98.731% |
| Virax Biolabs Group Limited | 5.48 Million USD | 55.762% |
| Cibus, Inc. | 544.41 Million USD | 99.554% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 98.073% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 88.191% |
| IN8bio, Inc. | 33.7 Million USD | 92.803% |
| Kodiak Sciences Inc. | 479.37 Million USD | 99.494% |
| Annexon, Inc. | 297.67 Million USD | 99.185% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 98.598% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 98.235% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | 88.444% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.919% |
| Eyenovia, Inc. | 28.77 Million USD | 91.57% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 98.948% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 66.417% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 96.018% |
| Arcellx, Inc. | 825.13 Million USD | 99.706% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 97.028% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 99.475% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 92.111% |
| Moolec Science SA | 24.05 Million USD | 89.913% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 99.218% |
| Geron Corporation | 394.07 Million USD | 99.384% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 97.615% |
| Royalty Pharma plc | 16.38 Billion USD | 99.985% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 99.592% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | 65.317% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | 79.829% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 98.927% |
| Humacyte, Inc. | 128.22 Million USD | 98.108% |
| Structure Therapeutics Inc. | 482.01 Million USD | 99.497% |
| 89bio, Inc. | 596.26 Million USD | 99.593% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 99.038% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -31.135% |
| Genelux Corporation | 27.89 Million USD | 91.302% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 97.286% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 98.943% |
| Notable Labs, Ltd. | 19.54 Million USD | 87.585% |
| Liquidia Corporation | 120.43 Million USD | 97.986% |
| Mustang Bio, Inc. | 17.74 Million USD | 86.326% |
| Immunovant, Inc. | 666.71 Million USD | 99.636% |
| Quantum-Si incorporated | 298.25 Million USD | 99.187% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 98.32% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 95.521% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 98.618% |
| Acasti Pharma Inc. | 73.3 Million USD | 96.69% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | 46.708% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 90.711% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 99.749% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | 53.256% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | 89.351% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 95.299% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 98.657% |
| PepGen Inc. | 143.05 Million USD | 98.304% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 93.652% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.966% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | 87.355% |
| Solid Biosciences Inc. | 164.93 Million USD | 98.529% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 58.687% |
| Immuneering Corporation | 102.58 Million USD | 97.635% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 43.694% |
| Silo Pharma, Inc. | 7.74 Million USD | 68.681% |
| Belite Bio, Inc | 94.64 Million USD | 97.437% |
| XOMA Corporation | 234.3 Million USD | 98.965% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 98.96% |
| Bionomics Limited | 27.64 Million USD | 91.226% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 99.396% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 97.741% |
| uniQure N.V. | 831.68 Million USD | 99.708% |
| Cassava Sciences, Inc. | 151.66 Million USD | 98.4% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 45.534% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 99.114% |
| Forte Biosciences, Inc. | 38.98 Million USD | 93.776% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | 40.439% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 93.413% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 66.417% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | 30.942% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | 79.477% |
| Altimmune, Inc. | 210.64 Million USD | 98.848% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 99.688% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 97.741% |
| Compugen Ltd. | 121.33 Million USD | 98.001% |
| Peak Bio, Inc. | 2.59 Million USD | 6.563% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 98.592% |
| Benitec Biopharma Inc. | 52.21 Million USD | 95.353% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 99.29% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 93.023% |
| Zura Bio Limited | 100.84 Million USD | 97.594% |
| PolyPid Ltd. | 15.37 Million USD | 84.218% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 97.966% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 93.023% |
| Instil Bio, Inc. | 325.63 Million USD | 99.255% |
| argenx SE | 4.54 Billion USD | 99.947% |
| Immunome, Inc. | 148.54 Million USD | 98.367% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 98.454% |
| Verona Pharma plc | 308.12 Million USD | 99.213% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 97.21% |
| Shattuck Labs, Inc. | 159.56 Million USD | 98.48% |
| CervoMed Inc. | 9.97 Million USD | 75.673% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 98.713% |
| Plus Therapeutics, Inc. | 11.38 Million USD | 78.697% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 98.648% |
| Moolec Science SA | 24.05 Million USD | 89.913% |
| Enveric Biosciences, Inc. | 6.11 Million USD | 60.343% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 98.597% |
| AnaptysBio, Inc. | 452.38 Million USD | 99.464% |
| Design Therapeutics, Inc. | 289.64 Million USD | 99.162% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 96.669% |
| NeurAxis, Inc. | 509.49 Thousand USD | -376.155% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | 55.223% |
| Lumos Pharma, Inc. | 40.63 Million USD | 94.03% |
| Achilles Therapeutics plc | 161.45 Million USD | 98.497% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 97.21% |
| 180 Life Sciences Corp. | 5.25 Million USD | 53.874% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 96.555% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 71.661% |
| Nutriband Inc. | 7.51 Million USD | 67.727% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 99.047% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 98.783% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 96.817% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 95.811% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 99.539% |
| Palisade Bio, Inc. | 14.05 Million USD | 82.736% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 98.846% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 99.834% |
| Neurogene Inc. | 222.57 Million USD | 98.91% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 99.625% |
| AEON Biopharma, Inc. | 6.84 Million USD | 64.558% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 99.465% |
| Sesen Bio, Inc. | 189.17 Million USD | 98.718% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 99.108% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | 82.307% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 99.689% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 99.091% |
| Athira Pharma, Inc. | 160.24 Million USD | 98.486% |
| Vaccinex, Inc. | 3.63 Million USD | 33.186% |
| HCW Biologics Inc. | 28.51 Million USD | 91.492% |
| XOMA Corporation | 234.3 Million USD | 98.965% |
| Nektar Therapeutics | 398.03 Million USD | 99.391% |
| Arvinas, Inc. | 1.3 Billion USD | 99.814% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 85.761% |
| Merus N.V. | 458.49 Million USD | 99.471% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 98.813% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 98.654% |
| Rezolute, Inc. | 132.73 Million USD | 98.172% |
| Clene Inc. | 52.34 Million USD | 95.365% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | 83.744% |
| BeyondSpring Inc. | 24.8 Million USD | 90.221% |
| Synlogic, Inc. | 75.55 Million USD | 96.789% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | 79.548% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | 74.092% |
| Peak Bio, Inc. | 2.59 Million USD | 6.563% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 98.612% |
| Krystal Biotech, Inc. | 818.35 Million USD | 99.704% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 98.991% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 99.666% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | 32.181% |
| MannKind Corporation | 475.19 Million USD | 99.489% |
| Ikena Oncology, Inc. | 192.09 Million USD | 98.737% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | 81.86% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 97.918% |
| Gossamer Bio, Inc. | 311.91 Million USD | 99.222% |
| CohBar, Inc. | 16.36 Million USD | 85.176% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 93.101% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 66.835% |
| Legend Biotech Corporation | 1.84 Billion USD | 99.869% |
| Mural Oncology plc | 301.74 Million USD | 99.196% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 92.228% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 57.292% |
| Disc Medicine, Inc. | 367.99 Million USD | 99.341% |
| Champions Oncology, Inc. | 26.13 Million USD | 90.716% |
| REGENXBIO Inc. | 573.97 Million USD | 99.577% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | 10.416% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 98.429% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | 79.91% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 99.287% |
| Vaxart, Inc. | 91.83 Million USD | 97.358% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 95.95% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 98.364% |
| Cellectis S.A. | 334.27 Million USD | 99.274% |
| Longeveron Inc. | 12.17 Million USD | 80.079% |
| Repare Therapeutics Inc. | 253.9 Million USD | 99.045% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.926% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 98.792% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 99.884% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -49.292% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 99.126% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 98.513% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 98.251% |
| Anixa Biosciences, Inc. | 25.52 Million USD | 90.494% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.989% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 99.79% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 80.135% |
| Veru Inc. | 50.59 Million USD | 95.205% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 94.674% |
| Cingulate Inc. | 3.49 Million USD | 30.516% |
| Passage Bio, Inc. | 150.54 Million USD | 98.389% |
| Context Therapeutics Inc. | 16.06 Million USD | 84.897% |
| Exicure, Inc. | 11.58 Million USD | 79.05% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 99.355% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 98.499% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | 86.115% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 99.271% |
| Nuvalent, Inc. | 732.38 Million USD | 99.669% |
| ABVC BioPharma, Inc. | 14.94 Million USD | 83.766% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 97.291% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | 82.905% |
| OmniAb, Inc. | 401.98 Million USD | 99.396% |
| Anew Medical, Inc. | 19.45 Million USD | 87.531% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | 90.923% |
| Lipocine Inc. | 23 Million USD | 89.453% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 98.265% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 99.206% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 97.11% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 98.004% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | 69.427% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 99.725% |
| Ocugen, Inc. | 64.54 Million USD | 96.241% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 98.052% |
| Q32 Bio Inc. | 306.11 Million USD | 99.207% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | 42.348% |
| Alumis Inc. Common Stock | 89.61 Million USD | 97.293% |
| Equillium, Inc. | 50.53 Million USD | 95.199% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 96.774% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 94.122% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -42.634% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 90.72% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 96.235% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 34.909% |
| Dominari Holdings Inc. | 57.55 Million USD | 95.785% |
| Edesa Biotech, Inc. | 8.89 Million USD | 72.712% |
| vTv Therapeutics Inc. | 11.01 Million USD | 77.981% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.914% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 99.741% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 99.701% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 99.126% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 94.183% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 99.637% |
| Nkarta, Inc. | 378.88 Million USD | 99.36% |
| BioCardia, Inc. | 2.98 Million USD | 18.781% |
| Iterum Therapeutics plc | 26.25 Million USD | 90.761% |